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Abstract
Pathogenic events leading to in-stent restenosis (ISR) are
still incompletely understood. Among others, inflamma-
tion, immune reactions, deregulated cell death and
growth have been suggested. Therefore, atherectomy
probes from 21 patients with symptomatic ISR were ana-
lyzed by immunohistochemistry for pathogen burden
and compared to primary target lesions from 20 stable
angina patients. While cytomegalovirus, herpes simplex
virus, Epstein-Barr virus and Helicobacter pylori were not
found in ISR, acute and/or persistent chlamydial infec-
tion were present in 6/21 of these lesions (29%). Expres-
sion of human heat shock protein 60 was found in 8/21 of
probes (38%). Indicated by distinct signals of CD68, CD40
and CRP, inflammation was present in 5/21 (24%), 3/21
(14%) and 2/21 (10%) of ISR cases. Cell density of ISR
was significantly higher than that of primary lesions (977
B 315 vs. 431 B 148 cells/mm2; p ! 0.001). There was no
replicating cell as shown by Ki67 or PCNA. TUNEL+ cells
indicating apoptosis were seen in 6/21 of ISR specimens
(29%). Quantitative analysis revealed lower expression
levels for each intimal determinant in ISR compared to
primary atheroma (all p ! 0.05). In summary, human ISR
at the time of clinical presentation is characterized by low
frequency of pathogen burden and inflammation, but
pronounced hypercellularity, low apoptosis and absence
of proliferation.
Copyright © 2004 S. Karger AG, Basel
Introduction
Coronary stent implantation is widely accepted as a
modality to prevent restenosis. However, intimal hyper-
plasia leading to in-stent restenosis (ISR) markedly limits
the long-term success of stenting by pathobiological
events that are still poorly understood [1, 2]. While ath-
erosclerosis is now regarded as a chronic inflammatory
disease in response to injury [3], ISR events in patients
has only been studied by a few reports dealing with ather-
ectomy probes [4–7] or post mortem tissue samples [8–
11].
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Several groups reported macrophages accumulated ad-
jacent to stent struts, suggesting that vascular wall injury
and/or stent material elicit inflammatory reactions [5, 8–
13]. In addition, infections with various bacterial and
viral pathogens have been associated with atherosclerotic
disease [3, 14]. Initial steps in atherosclerosis may result
from the direct cytopathic effect of the pathogen that
replicates in the vascular wall, or may be mediated by an
immune response directed against cellular antigens. As
suggested, chronic immune-mediated inflammatory re-
sponses in atherosclerosis may be antigen-specific and
directed against autoantigens or pathogen-derived struc-
tures [3]. Although possible associations between resteno-
sis with specific infectious agents have been proposed by
seroepidemiological studies that focused on cytomegalo-
virus (CMV), Chlamydia pneumoniae and intimal patho-
gen burden [15–20], to our knowledge, its presence in ISR
lesions has not yet been determined. Likewise, with
regard to the regulation of neointimal cellularity in clini-
cal restenosis, proliferative activity of smooth muscle cells
remains controversial [21, 22], whereas low levels of inti-
mal apoptosis post-balloon angioplasty compared to pri-
mary atheroma were previously reported by our group
[23]. Therefore, the present study was designed to system-
atically examine the extent of neointimal pathogen bur-
den, inflammation, proliferation and apoptosis in symp-
tomatic human ISR atherectomy probes.
Methods
Patients and Arterial Specimens
A series of 41 symptomatic patients (34 men and 7 women; mean
age 58 B 9 years) had been percutaneously treated by directional
atherectomy (Danimed, Isernhagen, Germany) [24, 25]. A total of 41
atherectomy probes were obtained, including 21 ISR lesions (13 cor-
onary, 7 peripheral), and 20 primary coronary lesions from patients
with stable angina (table 1). All patients received heparin intrave-
nously 30–60 min before and during the procedure. All patients had
given informed consent for subsequent analysis of excised plaque tis-
sue, and tissue collection was carried out under institutional Ethics
Committee-approved protocols.
Immunohistochemistry
Tissue samples were fixed in 4.5% buffered formaldehyde and
embedded in paraffin. Serial sections (4 Ìm) were dewaxed and rehy-
drated. After retrieval with 95°C citrate buffer (8 min, 3%), tissue
segments were incubated with rabbit serum (Dianova, Hamburg,
Germany, dilution 1:5), to block nonspecific binding sites. Sections
were treated with monoclonal anti-·-smooth muscle actin (clone
1A4, Sigma, Deisenhofen, Germany, 1:250), anti-CMV (clone CCH,
Dako, Hamburg, Germany, 1:10), anti-major outer membrane pro-
tein (MOMP; clone RR402, Dako, 1:100), anti-chlamydial HSP60
(clone A57-B9, Dianova, 1:250), anti-human HSP60 (clone 4Bo/89,
Dianova, 1:250), anti-CD68 (clone KP1, Dako, 1:100), anti-CD40
(clone B-B20, Dianova, 1:250) or anti-proliferation cell nuclear anti-
gene (PCNA; clone PC10, Becton Dickinson, Leiden, Netherlands,
1:10). For the polyclonal rabbit anti-CRP antibody (catalog no 68-
206, ICN-Biomedicals, Aurora, Ohio, USA, 1:250), retrieval was per-
formed with saponine (2%) and incubation with FCS (1:25) was
applied for 30 min at room temperature following primary antibody
incubation. The final reaction product was stained with the APAAP
kit (Dianova) and Fast Red (Sigma) as chromogen, according to stan-
dard protocols. Ki67 staining experiments were performed using the
avidin-biotin method: Briefly, after the inhibition of endogenous per-
oxidase activity with methanol and hydrogen peroxide (3%) and pre-
digestion with 95 °C citrate buffer, nonspecific binding sites were
blocked by normal goat serum (Dianova, 1:10). Sections were then
incubated with the Ki67 antibody (clone MIB-1, Dako, 1:100) for
40 min at 37 °C. Antibody binding was visualized with a biotinylated
goat antimouse antibody (Vector, Grünberg, Germany, 1:50), fol-
lowed by the ABC complex (Vector) and aminoethylcarbazole (ICN,
Eschwege, Germany) as chromogen. Nuclear counterstaining was
done by hematoxylin.
The terminal deoxynucleotidyl transferase (Tdt)-mediated
TUNEL test (in situ cell death detection kit, AP, Boehringer Mann-
heim, Germany) was used according to the manufacturer’s directions
and as described previously [23]. Herein, Tdt catalyzes the binding of
fluorescein-labeled nucleotides to free 3)-hydroxyl DNA ends in a
template-independent manner, thereby labeling DNA strand breaks.
Antifluorescein antibody sheep Fab fragments conjugated with alka-
line phosphatase were then used for former strand break detection.
Positive and negative controls were run with each test series: mam-
malian epithelial cells infected with Chlamydia pneumoniae (Medac,
Hamburg, Germany), lung tissue infected with CMV (Dako), carotid
arteries, tissues from a non-Hodgkin lymphoma for Ki67 and from
tonsil for TUNEL analysis served as positive controls. Negative con-
trols included omission of the antibodies staining with unspecific
antibody (mouse monoclonal IgG1, clone NCG01, Dianova and
ChromPure rabbit IgG, code number 011-000-003, Dianova, respec-
tively) in the same concentrations as the primary antibodies as well
as tissue samples taken from nonimplanted saphenous vein grafts
and normal mammary arteries. Negative controls for TUNEL in-
cluded omission of Tdt.
Morphometric analysis was done by use of a computer-assisted
morphometry system (VFG 1 graphic card/VIBAM 0.0. software).
Pictures were obtained with an Optiphot-2 microscope (Nikon, Düs-
seldorf, Germany) and a KP-C553CCD video camera (Hitachi, Rod-
gau, Germany). Morphometric data were evaluated in five randomly
selected areas (0.04 mm2 each) per cross-section by two independent
examiners.
Statistical Analysis
Data are reported as presence (percentage of determinant-posi-
tive lesions per total number of lesions) and expression [percentage
(mean B SEM) of stained cells per total number of cells]. We
assessed group differences by the use of ¯2 test for categorical vari-
ables. Probability was calculated with the Mann-Whitney U test for
differences in cell density and expression of intimal determinants.
Correlation coefficients were determined by Pearson’s test. p values
of !0.05 were considered to denote statistical significance.
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Table 1. Patients and lesion characteristics
No. Age Gender Risk factors Medication Treated
vessel
Number/weight
of plaques, mg
Time interval
months
In-stent restenosis
1 45 M F, L Lm LAD 9/56 2
2 45 M F, L Lm RCx 4/17 10
3 54 M O ACE, Be, Lm, Ni, As RCA 3/16 6
4 44 F L, O, N Be, Lm, As RCA 1/5 5
5 58 M H, L, F Be, As LAD 2/12 6
6 49 M L, N ACE, Be, Lm, Ni, As LAD 3/16 4
7 65 F H, L Lm, Ni, As Bypass 4/19 3
8 77 M D, L ACE, Lm, As RCA 5/25 5
9 60 M D, H, L ACE, Be, Ca, Lm ,As LAD 5/39 6
10 71 F D, H, L, O Be, Ca, Lm, Ni, As Bypass 3/17 12
11 54 M D, H, L ACE, Be, Lm, As RCx 3/10 7
12 66 M D, L Lm RCA 1/5 5
13 58 F H, L, F Be, As LAD 4/26 6
14 56 M L, O, N Lm, As RCA 2/13 6
15 74 F H, L, N ACE, Ca, Lm, As SFA 5/63 6
16 45 M L, N Lm, As SFA 4/29 6
17 60 M H, L, N ACE, Be, Lm, As SFA 8/132 4
18 60 M D, O Ca, As SFA 9/167 3
19 72 M D, H Lm, Ni, As SFA 3/54 6
20 60 M D ACE, Lm, Ni, As SFA 4/66 12
21 46 M H, L, N Lm, As IA 7/86 10
De novo lesions
1 62 F L, N ACE, Be, Ni, As RCx 3/20
2 69 M L Be, Ca, Lm, Ni, As LAD 3/11
3 61 M H, O, N Ni RCA 1/3
4 62 F H ACE, Ca, Ni, As RCA 2/6
5 50 M L, F Be, Lm, Ni, As LAD 5/12
6 53 M H, L, F ACE, Be, Ca, Lm, As RCA 4/9
7 66 M L Lm, Ni RCA 9/40
8 50 M L, O, F Lm LAD 7/45
9 59 M L Be, Ni, As LAD 8/49
10 48 M N Ni LAD 5/35
11 66 M D, H, F Be, Ni, As LAD 7/32
12 63 M F Ni, As RCA 1/8
13 61 M H ACE, Be, Lm, Ni, As LAD 7/28
14 51 M L, F, N ACE, Ca, Lm, Ni LAD 3/8
15 62 M L, F ACE, Ni RCA 4/13
16 69 M O As LAD 4/19
17 43 M H, L, N Ca, Ni, As LAD 8/41
18 48 M L ACE, Ni, As LAD 4/16
19 62 M H, O As, Lm LAD 5/12
20 62 M H, L, F ACE, Ca, Lm, As LAD 2/6
LAD = Left anterior descending; RCx = Ramus circumflexus; RCA = right coronary artery; SFA = superficial
femoral artery; IA = iliac artery; D = diabetes mellitus; H = hypertension; L = hyperlipidemia; F = familiar disposi-
tion; N = nicotine; O = obesity; ACE = ace inhibitor; Be = ß-blocker; Ca = calcium antagonist; Lm = antilipid medica-
tion; Ni = nitrate; As = aspirin.
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Table 2. Coronary and peripheral ISR
samples: lesion characteristics No. Cells/mm
2 Expression, %
MOMP cHSP60 hHSP60 CD68 CD40 CRP
1 1,421 0 0.1 0 0 0 0
2 1,562 0.5 0.6 0 0 0 0
3 984 0.2 0 0 0 0 0
4 810 0 0 0.4 0 0.6 0
5 1,426 0 0 0 0 0.8 0
6 999 0 0 0 0 0 0
7 858 0 0 0 3.1 0 0
8 1,260 0 0 0 0 0.6 0
9 738 0.2 0 0.5 0.7 0 0
10 785 0 0 0.1 0 0 0
11 762 0 0 0 0 0 0
12 1,093 0 0 0 0 0 0
13 1,175 0 0 0.6 0 0 0.6
14 535 0 0 0.5 0.7 0 0
15 394 0 0.4 0.5 0 0 0.3
16 645 0.3 2.4 0 0 0 0
17 1,437 0 0 0 0.3 0 0
18 879 0 0 0 0 0 0
19 989 1.2 8.9 18.7 0 0 0
20 1,025 0 0 0 0.6 0 0
21 737 0 3.2 1.6 0 0 0
™ 977B315 0.1B0.2 0.7B2.1 1.1B4.4 0.3B0.8 0.1B0.2 0.04B0.1
CMV, HSV, EBV, HP, Ki67 and PCNA were not found in ISR tissue; data are not shown
in table 1.
Results
ISR probes (n = 21) were compared to primary athero-
ma (n = 20) with respect to pathogen burden, inflamma-
tion markers, (neo)intimal cellularity, proliferation and
apoptosis. Demographics and medication of ISR patients
did not differ from those of primary lesion patients (ta-
ble 1). Comparison of cardiovascular risk factors revealed
a higher prevalence only for diabetes in the ISR group (p =
0.008), but not for hypertension, hyperlipidemia, familial
disposition, nicotine or obesity. ISR characteristics and
quantitative histopathological data are summarized in
table 2. Typical immunohistochemical examples of ISR
lesions illustrating the expression pattern of specific key
determinants are given in fig. 1–3. Summarized quantita-
tive data resulting from pathological examination of
atherectomy tissue are presented in fig. 4.
Infection/Pathogen Burden
ISR tissue did not show any signal indicating the pres-
ence of CMV (fig. 1a). In contrast, primary lesions re-
vealed CMV in 8 of 20 cases (40%); 2.3% of intimal cells
were positive for CMV (fig. 4). Evidence of Chlamydia
pneumoniae, indicated by the presence of chlamydial ma-
jor outer membrane protein (MOMP) for acute infection
and that of chlamydial heat shock protein 60 (cHSP60) for
chronic persistent infection, was found in 6/21 of the ISR
lesions (29%; fig. 1b), for each marker. Presence of the
human HSP60 homolog (hHSP60) was seen in 8/21 ISR
cases (38%; fig. 1c). In addition, lesions showed low expres-
sion levels of Chlamydia-associated determinants of !1%
(table 1, fig. 4). In contrast, primary lesions revealed immu-
noreaction in 11/20 (55%) of all cases for MOMP, 12/20
(60%) for cHSP60 and 13/20 (65%) for hHSP60, as well as
significantly higher lesional expression levels (fig. 4). While
herpes simplex virus (HSV), Epstein Barr virus (EBV) and
Helicobacter pylori (HP) were not present in any ISR sam-
ple, the percentage of immunolabeled cells for each of these
infectious pathogens was higher in primary lesions (fig. 4).
Whenever markers of infectious agents were observed, they
were not confined to particular plaque regions or predilec-
tion sites.
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Fig. 1. Photomicrographs of representative ISR lesions that demonstrate homogeneous hypercellularity (a) without
CMV presence, (b) with sparse signaling of cHSP60 indicative of chronic persistent chlamydial infections, (c) with
sparse immunostaining of the human HSP60 homolog, (d) with infrequent cell-bound signals of macrophages, (e)
without CRP expression, (f) with sparse CD40 immunoreactivity; thereby providing evidence for lack of infection
and inflammation in clinical ISR; bar = 50 Ìm.
Inflammation
Presence (24%) and expression (0.3%) of CD68+ mac-
rophages was markedly lower in ISR neointima (fig. 1d),
compared to 60% of primary lesions (fig. 2d) with CD68
expression in an average of 4.4% of the lesional cells (p =
0.003; fig. 4). However, in one case, focal aggregation of
macrophages was observed, suggesting adjacent stent ma-
terial in vivo. Similar to CD68, both CD40 and CRP were
sparse in 3/21 (14%) and 2/21 ISR lesions (10%), whereas
the same markers were present in 10/20 (50%) and 12/20
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Fig. 2. Photomicrographs of primay coronary lesions from patients with stable angina. Typical intimal localization of
(a) CMV, (b) cHSP60, (c) hHSP60, (d) CD68, (e) CRP and (f) CD40. Note that primary atheroma reveal significant-
ly higher intimal expression of these infectious and inflammatory determinants compared to ISR (fig. 1); bar =
50 Ìm.
(60%), respectively, of primary lesions (fig. 4). Quantita-
tively, pathogen burden indicated by the number of mi-
croorganisms present and expression of CRP correlated
significantly (r = 0.56, p ! 0.01).
Proliferation, Apoptosis
ISR probes consistently showed marked hypercellular-
ity compared to primary lesions (977 B 315 vs. 431 B
148 cells/mm2; p ! 0.001). The majority of all cells in ISR
expressed ·-smooth muscle actin (68 B 14%). Despite
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this pronounced cellularity in ISR lesions, there was no
evidence of ongoing proliferation in these specimens, as
indicated by Ki67 (fig. 3a). In contrast, Ki67 was ob-
served in 19/20 (95%) primary lesions, yielding a mean
expression of 1.9%. Additional experiments using PCNA
antibodies to assess cellular proliferation rates confirmed
the lack of cell replication in ISR specimens. Signals of
DNA strand breaks indicative for apoptosis were present
in 6/21 ISR lesions (29%; fig. 3c) and demonstrated a
markedly lower percentage of TUNEL-positive cells in
ISR versus primary lesions (1.2% vs. 12.0%; p ! 0.001).
Interestingly, there was no significant difference be-
tween the cellularity in ISR tissue from coronary or
peripheral vascular bed (1,034 B 275 vs. 863 B 380 cells/
mm2, p = 0.32) as well as between the expression profiles
of other studied markers. In addition, there was no rela-
tionship of either cellularity or expression of each studied
determinant and the time course after stent implanta-
tion.
Discussion
The present study analyzed pathogen burden, inflam-
mation, proliferation and apoptosis in human ISR ather-
ectomy probes versus primary atherosclerotic coronary
lesions. As the main finding, we herein demonstrate a
remarkably low frequency of both viruses and bacteria
within ISR lesions and thereby, were unable to show a
correlation between pathogen burden and ISR (fig. 1
and 4). Given the absence of both CMV and proliferation
in neointimal lesions (fig. 1a, 3a), previous suggestions of
CMV-dependent pathomechanisms in neointimal hyper-
plasia due to inhibition of proapoptotic p53 [19] are not
supported by our current findings. While these authors
reported that prior CMV infection increased the risk of
restenosis after directional atherectomy [19], others found
no correlation between previous CMV infection and in-
creased risk of restenosis after stenting [16]. As to Chla-
mydia pneumoniae, we report acute infection (MOMP)
and chronic persistence (cHSP60, fig. 1b) of this microor-
ganism in 29%, and corresponding human HSP60
(hHSP60, fig. 1c) in 38% of all ISR samples. Autoimmune
responses initiated by cross-reactions between microor-
ganism HSP and cellular self-components have been im-
plicated in atherogenesis [14, 18, 20, 26]. However, low
presence and expression levels of MOMP and cHSP60/
hHSP60 in ISR (fig. 1b, c) compared to primary lesions
(fig. 2c) suggest a negligible role of these determinants in
late neointima formation, if at all present. This may also
Fig. 3. Representative photomicrographs of in-stent resteno-
sis (ISR) tissue obtained from the left anterior descending of a
60-year-old patient 6 months after stent implantation (a, c,
d). a ISR lesion that exhibits no Ki67+ cells. b Positive con-
trol of human non-Hodgkin lymphoma containing many
Ki67+ stained nuclei that indicate ongoing proliferation.
c ISR lesion from the same patient that shows a low percent-
age of TUNEL+ cells. Of note, parts of media or adventitia
were not found in any ISR specimen. Bar = 50 Ìm.
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Fig. 4. Presence and expression of pathogen
burden (CMV, cytomegalovirus, MOMP,
chlamydial major outer membrane protein,
cHSP60, chlamydial heat shock protein 60,
hHSP60, human heat shock protein 60,
HSV, Herpes simplex virus, EBV, Epstein
Barr virus, HP, Helicobacter pylori), inflam-
mation (CD68, macrophages, CD40; CRP,
C-reactive protein) and proliferation (Ki-67)
was significantly lower in 21 ISR ($) versus
20 primary lesions ()). * p ! 0.05, ** p !
0.001.
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explain the poor clinical outcome within recent antibiotic
trials to mitigate ISR [17]. Likewise, neither herpes sim-
plex virus, Epstein-Barr virus nor Helicobacter pylori,
infectious pathogens implicated in certain cardiovascular
diseases [15, 20, 27], were found in ISR probes removed
from symptomatic patients.
In the present study, a few, if any, cells in ISR probes
were macrophages (fig. 1d). Since inflammatory cells are
commonly found in plaques from patients with acute cor-
onary syndromes [12, 28], we exclusively studied coro-
nary primary atheroma associated with stable angina as
controls. Recent autopsy studies early post-stent implan-
tation described macrophage accumulations near stent
struts [8–10], and thereby suggested the importance of
inflammatory reactions also in neointima formation.
Farb et al. [13] found a correlation between the extent of
stent strut-adjacent inflammation, medial damage and
restenosis in human ISR lesions studied in autopsy mate-
rial excised at a mean of 10 months postimplantation.
However, this autopsy study analyzed deep regions close
to stent struts, irrespective of clinical or histological ISR,
whereas our study is strictly confined to the upper parts of
ISR neointima that had been ex vivo retrieved by direc-
tional atherectomy within symptomatic patients. Further
evidence for a link between leukocytes and restenosis had
been provided by previous work on atherectomy probes
revealing a positive correlation between the macrophage
number in atheroma at the time of angioplasty and subse-
quent propensity of restenosis [29]. However, other stud-
ies that had analyzed ISR tissue at a late phase demon-
strated only minimal inflammatory cells [4, 5], compara-
ble to our present data. In addition, macrophage presence
is further supported by low cell-bound CD40 and CRP
expression levels within ISR lesions (fig. 1e, f).
Several possibilities could account for the apparent
lack of both infection and inflammation in human ISR.
Predisposition of primary atheroma devoid of pathogen
burden/inflammation to develop ISR has not been sup-
ported by a broad body of literature [19, 30, 31]. Also, we
demonstrate primary lesions to exhibit pronounced
pathogen burden and to contain high levels of several
inflammation-associated determinants. Therefore, in-
flammatory processes may not be basically implicated in
late hyperplastic ISR or are widely completed with onset
of clinical ISR. Thereby, our data may give another piece
of evidence to the concept that apparently not mural
smooth muscle cells, but other cell types such as bonemar-
row-derived progenitor cells – devoid of infection – may
participate in wound healing. Indeed, a few reports
showed the presence of bone-marrow cells in solid neotin-
ima [6, 32, 33].
Another characteristic feature of human ISR was its
pronounced hypercellularity (table 2) that significantly
differed from primary lesion cell density, consistent with
previous reports of others and our group [6, 23, 34].
Hypercellular neointima formation has been attributed to
smooth muscle cell migration, proliferation and mitigated
apoptosis [23, 34]. Likewise, in the present study, ISR tis-
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sue was predominantly composed of ·-SM actin-positive
cells. However, ISR specimens contained no replicating
cells, as indicated by the lack of Ki67 and PCNA labeling
(fig. 3). This is supported by previous reports on restenot-
ic atherectomy probes that demonstrated no or insignifi-
cant proliferation at the time of tissue removal [4, 31].
Admittedly, our present findings differ from other reports
that showed increased proliferative activity in post-bal-
loon restenosis [22] and in human ISR samples [5, 35].
These contradictory results may be attributed to different
time intervals between the first and second intervention,
since most proliferative responses are completed within
the first month post-vascular trauma [36]. Moreover, we
now demonstrate that the incidence of programmed cell
death in late ISR lesions is significantly reduced com-
pared to primary atheroma (fig. 3), extending previous
findings of our group that demonstrated mitigated apop-
tosis late, following balloon angioplasty [23]. Therefore,
decreased apoptosis may be regarded as the key mecha-
nism implicated in hypercellular neointima formation
post-vascular trauma. Of course, any observation on hu-
man tissue obtained by atherectomy (1) is limited by
reflecting only one single time point and (2) cannot exam-
ine early inflammatory and proliferative events known
from longitudinal animal studies [1, 2, 33]. Although no
significant relationship was found between the amount of
the studied markers and several cardiovascular risk fac-
tors and/or specific medications, the possibility that these
determinants may have influence on the ISR formation
by effects on vascular inflammation, proliferation and/or
apoptosis, as reported by others [37, 38], cannot be defini-
tively excluded.
Taken together, the present ex vivo study clearly dem-
onstrates that (1) frequency of intimal pathogens (CMV,
acute and chronic persistent chlamydial infection, HSV,
EBV, HP) is low or insignificant, (2) presence of hHSP60,
inflammatory cells or inflammatory markers is sparse,
(3) pronounced hypercellularity in clinical ISR coincides
with minimal cell replication and death levels, (4) all find-
ings on human ISR were consistently independent of vas-
cular origin and (5) apparently without time dependency
after stent implantation. Our findings may contribute to
better understand ISR and explain why antiinflammato-
ry/antibiotic therapies for its prevention that had been
suggested by animal models have not been successful so
far in clinical practice.
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